Single-use scopes take center stage at Ambu as core business areas recede
Ambu's traditional core business, Anaesthesia and Patient Monitoring & Diagnostics (PMD), is now playing a supporting role to single-use endoscopes, which account for most of the medtech company's sales growth. Ambu will still ensure that its former core business remains competitive, but development funding is now going in a different direction.
Photo: Ambu / PR
BY ULRICH QUISTGAARD, TRANSLATED BY DANIEL PEDERSEN
Medtech company Ambu's year has been somewhat of a mixed bag.
The actual risk of competition from generic drugs is limited, according to Jefferies analyst, although pharmaceutical company Viatris is challenging patents related to Novo Nordisk’s semaglutide.
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
Already in May of last year, the FDA released a report documenting quality control failures at Novo Nordisk’s factory in Clayton, USA, Reuters reports. (Updated)
Inadequate oversight of batch deviations and messy microbial controls are the cause of an FDA Form 483 for a Novo Nordisk plant in the US, reports media outlet Fierce Pharma.
With increasing competition in the hearing aid market, Jyske Bank analyst Janne Vincent Kjær does not expect Demant to continue its strong momentum into 2024.